Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Department of Justice
Baxter
Colorcon
Teva
Argus Health
Boehringer Ingelheim
Cerilliant
UBS
US Army

Generated: January 22, 2018

DrugPatentWatch Database Preview

SEROQUEL Drug Profile

« Back to Dashboard

Which patents cover Seroquel, and what generic alternatives are available?

Seroquel is a drug marketed by Astrazeneca Pharms and Astrazeneca and is included in two NDAs. There is one patent protecting this drug and seven Paragraph IV challenges.

The generic ingredient in SEROQUEL is quetiapine fumarate. There are fifty-two drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the quetiapine fumarate profile page.
Drug patent expirations by year for SEROQUEL
Pharmacology for SEROQUEL
Medical Subject Heading (MeSH) Categories for SEROQUEL

US Patents and Regulatory Information for SEROQUEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-001 Sep 26, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-006 Oct 4, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-004 Dec 20, 1998 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-004 May 17, 2007 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-001 May 17, 2007 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-007 Oct 4, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-002 Sep 26, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-005 Jul 26, 2000 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-003 Sep 26, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-002 May 17, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for SEROQUEL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-001 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-006 Oct 4, 2005 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-003 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-005 Jul 26, 2000 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-007 Oct 4, 2005 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-002 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-004 Dec 20, 1998 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SEROQUEL
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 150 mg ➤ Subscribe 11/17/2008
➤ Subscribe Extended-release Tablets 50 mg ➤ Subscribe 10/17/2008
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 6/18/2008
➤ Subscribe Tablets 200 mg and 300 mg ➤ Subscribe 6/12/2008
➤ Subscribe Tablets 50 mg, 150 mg and 400 mg ➤ Subscribe 2/12/2007
➤ Subscribe Tablets 100 mg, 200 mg and 300 mg ➤ Subscribe 2/21/2006
➤ Subscribe Tablets 25 mg ➤ Subscribe 8/12/2005

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Federal Trade Commission
Novartis
Accenture
Daiichi Sankyo
Medtronic
Dow
Teva
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot